Table 8Odds ratios of treatment success by duration of intensive phase and total treatment

Duration of intensive phase of treatmentTotal duration of treatmenta
Duration (months)ObservationsAdjustedb odds ratio (95% CLs)Duration (months)ObservationsAdjustedb odds ratio (95% CLs)
1–2.53081.0 (ref)6.0–12.57431.0 (ref)
2.6–4.014061.2 (0.5–2.9)12.6–15.53842.4 (1.5–3.6)
4.1–5.54812.4 (1.3–4.3)15.6–18.516464.6 (2.0–10.4)
5.6–7.03773.7 (1.9–7.1)18.6–21.56129.3 (5.8–15.0)
7.1–8.51725.1 (2.1–12.7)21.6–24.54356.8 (4.2–11.1)
8.6–207922.2 (1.2–3.9)24.6–27.52078.2 (4.2–15.9)
27.6–30.51062.4 (1.2–5.0)
30.6–36481.3 (0.6–2.7)
a

Only in patients with no previous treatment for MDR-TB.

b

Adjusted for age, sex, HIV status, previous TB treatment, previous MDR-TB treatment and extent of disease.

CLs = Confidence Limits

From: 4, Duration of second-line anti-tuberculosis regimens

Cover of Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis
Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update.
Copyright © 2011, World Health Organization.

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.